Regional differences in antibiotic-resistant pathogens in patients with pneumonia: Implications for clinicians

Respirology

Volumn 22, Issue 8, 2017, Pages 1536-1546

  Shindo, Yuichiro ^a   Hasegawa, Yoshinori ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

bacterial pneumonia, ventilator associated pneumonia; drug resistance; risk assessment; risk factors

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIUM ISOLATE; COMMUNITY ACQUIRED PNEUMONIA; DRUG CHOICE; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; HEALTH CARE ASSOCIATED PNEUMONIA; HOSPITALIZATION; HUMAN; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; MYCOPLASMA PNEUMONIAE; NONHUMAN; PHYSICIAN; PNEUMONIA; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; VENTILATOR ASSOCIATED PNEUMONIA; BACTERIAL PNEUMONIA; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HOSPITALIZATION; HUMANS; PNEUMONIA, BACTERIAL; PREVALENCE; RISK FACTORS;

EID: 85026738982     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.13135     Document Type: Review

References (64)

1. World Health Organization. Antimicrobial resistance, 2016. [Accessed 25 Jan 2017.] Available from URL: http://www.who.int/mediacentre/factsheets/fs194/en/
2. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462–74.
3. Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, Imaizumi K, Sato T, Hasegawa Y. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest 2009; 135: 633–40.
4. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262–8.
5. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171: 388–416.
6. Carratala J, Mykietiuk A, Fernandez-Sabe N, Suarez C, Dorca J, Verdaguer R, Manresa F, Gudiol F. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch. Intern. Med. 2007; 167: 1393–9.
7. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 3854–62.
8. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob. Agents Chemother. 2007; 51: 3568–73.
9. Park HK, Song JU, Um SW, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ, Jeon K. Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital. Respir. Med. 2010; 104: 1729–35.
10. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin. Infect. Dis. 2014; 58: 330–9.
11. Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, Choudhury G, Hill AT. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin. Infect. Dis. 2011; 53: 107–13.
12. Garcia-Vidal C, Viasus D, Roset A, Adamuz J, Verdaguer R, Dorca J, Gudiol F, Carratala J. Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clin. Microbiol. Infect. 2011; 17: 1659–65.
13. Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect. Dis. 2010; 10: 279–87.
14. Falcone M, Venditti M, Shindo Y, Kollef MH. Healthcare-associated pneumonia: diagnostic criteria and distinction from community-acquired pneumonia. Int. J. Infect. Dis. 2011; 15: e545–50.
15. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, Goto Y, Fukui Y, Iwaki M, Okumura J et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2013; 188: 985–95.
16. Self WH, Wunderink RG, Williams DJ, Barrett TW, Baughman AH, Grijalva CG. Comparison of clinical prediction models for resistant bacteria in community-onset pneumonia. Acad. Emerg. Med. 2015; 22: 730–40.
17. Webb BJ, Dascomb K, Stenehjem E, Vikram HR, Agrwal N, Sakata K, Williams K, Bockorny B, Bagavathy K, Mirza S et al. The DRIP score: derivation and prospective multi-center validation of a model to predict drug resistance in community-onset pneumonia. Antimicrob. Agents Chemother. 2016; 60: 2652–63.
18. Webb BJ, Jones B, Dean NC. Empiric antibiotic selection and risk prediction of drug-resistant pathogens in community-onset pneumonia. Curr. Opin. Infect. Dis. 2016; 29: 167–77.
19. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratala J et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin. Infect. Dis. 2016; 63: e61–111.
20. Ishida T, Ito A, Washio Y, Yamazaki A, Noyama M, Tokioka F, Arita M. Risk factors for drug-resistant pathogens in immunocompetent patients with pneumonia: evaluation of PES pathogens. J. Infect. Chemother. 2017; 23: 23–8.
21. Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, Micek ST, Kollef MH. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin. Infect. Dis. 2012; 54: 193–8.
22. Shorr AF, Myers DE, Huang DB, Nathanson BH, Emons MF, Kollef MH. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect. Dis. 2013; 13: 268.
23. Prina E, Ranzani OT, Polverino E, Cilloniz C, Ferrer M, Fernandez L, Puig de la Bellacasa J, Menendez R, Mensa J, Torres A. Risk factors associated with potentially antibiotic resistant pathogens in community-acquired pneumonia. Ann. Am. Thorac. Soc. 2015; 12: 153–60.
24. Park SC, Kang YA, Park BH, Kim EY, Park MS, Kim YS, Kim SK, Chang J, Jung JY. Poor prediction of potentially drug-resistant pathogens using current criteria of health care-associated pneumonia. Respir. Med. 2012; 106: 1311–9.
25. Falcone M, Russo A, Giannella M, Cangemi R, Scarpellini MG, Bertazzoni G, Alarcon JM, Taliani G, Palange P, Farcomeni A et al. Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia. PLoS One 2015; 10: e0119528.
26. Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, Tarsia P, Mantero M, Blasi F. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin. Infect. Dis. 2012; 54: 470–8.
27. Wang PH, Wang HC, Cheng SL, Chang HT, Laio CH. Selection of empirical antibiotics for health care-associated pneumonia via integration of pneumonia severity index and risk factors of drug-resistant pathogens. J. Formos. Med. Assoc. 2016; 115: 356–63.
28. Madaras-Kelly KJ, Remington RE, Fan VS, Sloan KL. Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare-associated pneumonia. J. Hosp. Med. 2012; 7: 195–202.
29. Ma HM, Ip M, Woo J, Hui DS. Development and validation of a clinical risk score for predicting drug-resistant bacterial pneumonia in older Chinese patients. Respirology 2014; 19: 549–55.
30. El Solh AA, Pietrantoni C, Bhat A, Bhora M, Berbary E. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin. Infect. Dis. 2004; 39: 474–80.
31. Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr. Opin. Infect. Dis. 2009; 22: 316–25.
32. Schreiber MP, Chan CM, Shorr AF. Resistant pathogens in nonnosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia? Chest 2010; 137: 1283–8.
33. Wunderink RG. Community-acquired pneumonia versus healthcare-associated pneumonia. The returning pendulum. Am. J. Respir. Crit. Care Med. 2013; 188: 896–8.
34. Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N. Engl. J. Med. 2014; 370: 543–51.
35. Hui DS, Ip M, Ling T, Chang SC, Liao CH, Yoo CG, Kim DK, Yoon HI, Udompanich V, Mogmeud S et al. A multicentre surveillance study on the characteristics, bacterial aetiologies and in vitro antibiotic susceptibilities in patients with acute exacerbations of chronic bronchitis. Respirology 2011; 16: 532–9.
36. Yamaguchi K, Ohno A, Ishii Y, Tateda K, Iwata M, Levofloxacin-Surveillance Group. In vitro susceptibilities to levofloxacin and various antibacterial agents of 12,866 clinical isolates obtained from 72 centers in 2010. Jpn. J. Antibiot. 2012; 65: 181–206.
37. Zhanel GG, Adam HJ, Baxter MR, Fuller J, Nichol KA, Denisuik AJ, Lagace-Wiens PR, Walkty A, Karlowsky JA, Schweizer F et al.; Canadian Antimicrobial Resistance Alliance. Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007–11 study. J. Antimicrob. Chemother. 2013; 68(Suppl. 1): i7–22.
38. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007; 44(Suppl. 2): S27–72.
39. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G et al.; Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections--full version. Clin. Microbiol. Infect. 2011; 17(Suppl. 6): E1–59.
40. World Health Organization. Antimicrobial resistance: global report on surveillance 2014, 2014. [Accessed 25 Jan 2017.] Available from URL: http://www.who.int/antimicrobial-resistance/publications/surveillancereport/en/
41. Aliberti S, Reyes LF, Faverio P, Sotgiu G, Dore S, Rodriguez AH, Soni NJ, Restrepo MI, GLIMP Investigators. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect. Dis. 2016; 16: 1364–76.
42. Ma HM, Ip M, Woo J, Hui DS, Lui GC, Lee NL, Chan PK, Rainer TH. Risk factors for drug-resistant bacterial pneumonia in older patients hospitalized with pneumonia in a Chinese population. QJM 2013; 106: 823–9.
43. Charles PG, Whitby M, Fuller AJ, Stirling R, Wright AA, Korman TM, Holmes PW, Christiansen KJ, Waterer GW, Pierce RJ et al. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin. Infect. Dis. 2008; 46: 1513–21.
44. Ewig S, Klapdor B, Pletz MW, Rohde G, Schutte H, Schaberg T, Bauer TT, Welte T, CAPNETZ Study Group. Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study. Thorax 2012; 67: 132–8.
45. Bjarnason A, Asgeirsson H, Baldursson O, Kristinsson KG, Gottfredsson M. Mortality in healthcare-associated pneumonia in a low resistance setting: a prospective observational study. Infect. Dis. (Lond.) 2015; 47: 130–6.
46. Self WH, Wunderink RG, Williams DJ, Zhu Y, Anderson EJ, Balk RA, Fakhran SS, Chappell JD, Casimir G, Courtney DM et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clin. Infect. Dis. 2016; 63: 300–9.
47. Gross AE, Van Schooneveld TC, Olsen KM, Rupp ME, Bui TH, Forsung E, Kalil AC. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob. Agents Chemother. 2014; 58: 5262–8.
48. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch. Intern. Med. 2008; 168: 2205–10.
49. Webb BJ, Dascomb K, Stenehjem E, Dean N. Predicting risk of drug-resistant organisms in pneumonia: moving beyond the HCAP model. Respir. Med. 2015; 109: 1–10.
50. Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, Pesci A, Blasi F, Torres A. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. Thorax 2013; 68: 997–9.
51. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 1997; 336: 243–50.
52. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377–82.
53. Postma DF, van Werkhoven CH, van Elden LJ, Thijsen SF, Hoepelman AI, Kluytmans JA, Boersma WG, Compaijen CJ, van der Wall E, Prins JM et al.; CAP-START Study Group. Antibiotic treatment strategies for community-acquired pneumonia in adults. N. Engl. J. Med. 2015; 372: 1312–23.
54. Shindo Y, Hasegawa Y. Macrolide therapy for patients with pneumonia: a triple-edged sword. In: Aliberti S, Chalmers JD, Pletz M (eds) Anti-Infectives and the Lung (ERS Monograph). Sheffield, European Respiratory Society, 2017; 206–31.
55. Zheng X, Lee S, Selvarangan R, Qin X, Tang YW, Stiles J, Hong T, Todd K, Ratliff AE, Crabb DM et al. Macrolide-resistant Mycoplasma pneumoniae, United States. Emerg. Infect. Dis. 2015; 21: 1470–2.
56. Zhao F, Liu G, Wu J, Cao B, Tao X, He L, Meng F, Zhu L, Lv M, Yin Y et al. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob. Agents Chemother. 2013; 57: 1521–3.
57. Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101. Antimicrob. Agents Chemother. 2009; 53: 2139–41.
58. Barrera CM, Mykietiuk A, Metev H, Nitu MF, Karimjee N, Doreski PA, Mitha I, Tanaseanu CM, Molina JM, Antonovsky Y et al.; for the SOLITAIRE-ORAL Pneumonia Team. Efficacy and safety of oral solithromycin versus oral moxifloxacin for treatment of community-acquired bacterial pneumonia: a global, double-blind, multicentre, randomised, active-controlled, non-inferiority trial (SOLITAIRE-ORAL). Lancet Infect. Dis. 2016; 16: 421–30.
59. File TM Jr, Rewerska B, Vucinic-Mihailovic V, Gonong JR, Das AF, Keedy K, Taylor D, Sheets A, Fernandes P, Oldach D et al.; for the SOLITAIRE-IV Pneumonia Team. SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin. Infect. Dis. 2016; 63: 1007–16.
60. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Goto Y, Fukui Y, Iwaki M, Okumura J, Yamaguchi I et al.; Central Japan Lung Study Group. Risk factors for 30-day mortality in patients with pneumonia who receive appropriate initial antibiotics: an observational cohort study. Lancet Infect. Dis. 2015; 15: 1055–65.
61. Falcone M, Corrao S, Licata G, Serra P, Venditti M. Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study. Intern. Emerg. Med. 2012; 7: 523–31.
62. Metersky ML, Frei CR, Mortensen EM. Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia. Respirology 2016; 21: 157–63.
63. Wooten DA, Winston LG. Risk factors for methicillin-resistant Staphylococcus aureus in patients with community-onset and hospital-onset pneumonia. Respir. Med. 2013; 107: 1266–70.
64. Wu CL, Ku SC, Yang KY, Fang WF, Tu CY, Chen CW, Hsu KH, Fan WC, Lin MC, Chen W et al. Antimicrobial drug-resistant microbes associated with hospitalized community-acquired and healthcare-associated pneumonia: a multi-center study in Taiwan. J. Formos. Med. Assoc. 2013; 112: 31–40.